elements of nature magic
NEW YORK, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Color Star Technology Co., Ltd. (Nasdaq: ADD) (“Color Star” or the “Company”), an entertainment technology company with a global network that focuses on the application of technology and artificial intelligence in the entertainment industry, announced today that it received a formal notification from the Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires the Company’s ordinary shares to maintain a minimum bid price of $1.00 per share. The Nasdaq staff made this determination of compliance after the closing bid price of the Company’s Class A Ordinary Shares has been at $1.00 per share or greater for the last 10 consecutive business days from November 15, 2024 to November 29, 2024. Accordingly, the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2) and this bid price deficiency matter is now closed. About Color Star Technology Co., Ltd. Color Star Technology Co., Ltd. (Nasdaq: ADD) is an entertainment and education company that provides online entertainment performances and online music education services. Its business operations are conducted through its wholly-owned subsidiaries, Color Metaverse Pte. Ltd. and CACM Group NY, Inc. The Company’s online education is provided through its Color World music and entertainment education platform. More information about the Company can be found at www.colorstarinternational.com and www.colorstar.investorroom.com . Forward-Looking Statements This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantee of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company's goals and strategies; the Company's future business development, including the development of the metaverse project; product and service demand and acceptance; changes in technology; economic conditions; the growth of the educational and training services market internationally where ADD conducts its business; reputation and brand; the impact of competition and pricing; government regulations; the ability of Color Star to meet NASDAQ listing standards in connection with the consummation of the transaction contemplated therein; and other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the Securities and Exchange Commission by Color Star. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the U.S. Securities and Exchange Commission, which are available for review at www.sec.gov . The Company undertakes no obligation to publicly revise these forward–looking statements to reflect events or circumstances that arise after the date hereof unless required by applicable laws, regulations or rules. Contact Color Star Investor Relations Office Number No. 1003, 9th Floor, 7 World Trade Center, Suite 4621 New York NY 10007 Office: (212) 410-5186 Email ir@colorstarinternational.comReports: Bill Belichick interviews for North Carolina job
NoneFlag football scours nation with talent camps to uncover next wave of starsOnly about 2 in 10 Americans approve of Biden's pardon of his son Hunter, poll finds
Key LTE Advanced Pro Market Trend 2024-2033: Advancements in Wi-Fi Router Technology
Only about 2 in 10 Americans approve of Biden's pardon of his son Hunter, poll finds
Joe Burrow's home broken into during Monday Night Football in latest pro-athlete home invasion
UCL: Late drama as Leverkusen end Inter’s perfect defensive runAdventures on special teams made the Washington-Dallas showdown a clumsy affair, yet Joe Davis and Greg Olsen saw to it that the broadcast of the chaotic finish was pure gold. After Terry McLaurin weaved his way past five defenders for an 86-yard touchdown catch from Jayden Daniels to cut the Cowboys lead to 27-26 with 21 seconds left, Fox's No. 2 broadcast crew captured the chaos before admonishing the audience not to count on anything as a certainty on this helter-skelter afternoon. "Lightning strikes twice in Washington!" Davis shouted in an homage to Daniels' 52-yard Hail Mary to Noah Brown that stunned the Bears last month. "They dropped 11 guys in coverage," Olsen marveled. "If they just tackle him inbounds the game is over. I don't even know what to say. I'm absolutely speechless." Not for long he wasn't. Olsen quickly cautioned the audience that "Automatic" Austin Siebert had already missed an extra point along with a field goal Sunday in his return from a right hip injury. "Before anyone in Washington gets too fired up, remember, we've seen a missed PAT already," Olsen said. "Yeah, you hold your breath with anything special teams-related on this day," Davis agreed. After all, this was the first game in NFL history to feature two kickoff returns for touchdowns, two errant extra points and a blocked punt. In the 41-point fourth quarter that erased the game's snoozer status, Washington allowed KaVontae Turpin's 99-yard kickoff return for a score. Earlier, the Cowboys missed a field goal and saw another one blocked along with a punt. Sure enough, the snap was low ... the hold was better ... "It is no good!" Davis hollered. "And the worst special teams day in history has a fitting finish!" Actually, no. More ruckus remained. Siebert's onside kick bounced twice in front of safety Juanyeh Thomas, who gathered it in and returned it 43 yards for Dallas' second kickoff return for a touchdown. If Thomas takes a knee short of the goal line, he effectively seals the Cowboys' win. Instead, the score, while pushing Dallas' lead to 34-26, also left enough time for Daniels and the Commanders for a shot at yet another miracle touchdown. Austin Ekeler returned the kickoff to the Washington 36 and after a short gain, Daniels' Hail Mary was intercepted by Israel Mukuamu as time expired. And that's how what Davis called the "worst special teams day in NFL history" came to an end. "What a wild special teams moment of blocked punts, kicks, kickoff returns, blocked field goals," Commanders coach Dan Quinn said. In keeping with the not-so-special-teams theme, there were several foibles in the kicking game across the NFL in Week 12, where the Broncos gave up a 34-yard pass completion on a fake punt that Denver coach Sean Payton swore the team saw coming — and not as it was unfolding, either, but five days earlier. "We met Tuesday as a staff. It wasn't a matter of if, it was when they were going to run a fake punt," Payton said. "You're struggling as a team like this, we had it on the keys to victory, so credit them, they executed it." Thanks to AJ Cole's 34-yard pass to linebacker Divine Deablo that set up a second-quarter field goal, the reeling Raiders took a 13-9 advantage into the locker room, just their second halftime lead of the season. In the second half, the Raiders succumbed to surging rookie QB Bo Nix and veteran wide receiver Courtland Sutton in their 29-19 loss. That's seven straight losses for the Raiders, their longest skid in a decade. The Broncos (7-5), who blew a chance to beat the Chiefs in Week 10 when their 35-yard field goal try was blocked as time ran out, also allowed a 59-yard kickoff return that led to Las Vegas' only touchdown Sunday. The Texans (7-5) lost for the third time in four games after Ka'imi Fairbairn shanked a 28-yard field goal try that would have tied the Titans just after the two-minute warning. Like the Broncos, the Vikings (9-2) overcame a special teams blunder and escaped Soldier Field with a 30-27 overtime win against the Bears after allowing Chicago (4-7) to recover an onside kick with 21 seconds left. Caleb Williams followed with a 27-yard pass to D.J. Moore to set up Cairo Santos' tying 48-yard field goal as the fourth-quarter clock hit zeros. Get local news delivered to your inbox!
Veralto Co. (NYSE:VLTO) Plans Quarterly Dividend of $0.11
Billionaires' wealth more than doubles in 10 years: UBSDonald Trump selects Kevin Hassett to lead National Economic Council
JERUSALEM — Israel approved a United States-brokered ceasefire agreement with Lebanon's Hezbollah on Tuesday, setting the stage for an end to nearly 14 months of fighting linked to the ongoing war in the Gaza Strip. In the hours leading up to the Cabinet meeting, Israel carried out its most intense wave of strikes in Beirut and its southern suburbs and issued a record number of evacuation warnings. At least 24 people were killed in strikes across the country, according to local authorities, as Israel signaled it aims to keep pummeling Hezbollah in the final hours before any ceasefire takes hold. Israel's security Cabinet approved the ceasefire agreement late Tuesday after it was presented by Prime Minister Benjamin Netanyahu, his office said. U.S. President Joe Biden, speaking in Washington, called the agreement “good news” and said his administration would make a renewed push for a ceasefire in Gaza. An Israel-Hezbollah ceasefire would mark the first major step toward ending the regionwide unrest triggered by Hamas’ attack on Israel on Oct. 7, 2023. But it does not address the devastating war in Gaza. U.S. President-elect Donald Trump has vowed to bring peace to the Middle East, but neither he nor Netanyahu have proposed a postwar solution for the Palestinian territory, where Hamas is still holding dozens of hostages and the conflict is more intractable. Still, any halt to the fighting in Lebanon is expected to reduce the likelihood of war between Israel and Iran, which backs both Hezbollah and Hamas and exchanged direct fire with Israel on two occasions earlier this year. Smoke rises following an Israeli airstrike on Dahiyeh, in Beirut, Lebanon, Tuesday, Nov. 26, 2024. Netanyahu presented the ceasefire proposal to Cabinet ministers after a televised address in which he listed a series of accomplishments against Israel’s enemies across the region. He said a ceasefire with Hezbollah would further isolate Hamas in Gaza and allow Israel to focus on its main enemy, Iran, which backs both groups. “If Hezbollah breaks the agreement and tries to rearm, we will attack,” he said. “For every violation, we will attack with might.” Netanyahu's office later said Israel appreciated the U.S. efforts in securing the deal but "reserves the right to act against every threat to its security.” It was not immediately clear when the ceasefire would go into effect, and the exact terms of the deal were not released. The deal calls for a two-month initial halt in fighting and would require Hezbollah to end its armed presence in a broad swath of southern Lebanon, while Israeli troops would return to their side of the border. Thousands of additional Lebanese troops and U.N. peacekeepers would deploy in the south, and an international panel headed by the United States would monitor all sides’ compliance. But implementation remains a major question mark. Israel has demanded the right to act should Hezbollah violate its obligations. Lebanese officials have rejected writing that into the proposal. Biden said Israel reserved the right to quickly resume operations in Lebanon if Hezbollah breaks the terms of the truce, but that the deal "was designed to be a permanent cessation of hostilities.” Hezbollah has said it accepts the proposal, but a senior official with the group said Tuesday that it had not seen the agreement in its final form. “After reviewing the agreement signed by the enemy government, we will see if there is a match between what we stated and what was agreed upon by the Lebanese officials,” Mahmoud Qamati, deputy chair of Hezbollah’s political council, told the Al Jazeera news network. “We want an end to the aggression, of course, but not at the expense of the sovereignty of the state” of Lebanon, he said. “Any violation of sovereignty is refused.” In this screen grab image from video provide by the Israeli Government Press Office, Israeli Prime Minister Benjamin Netanyahu makes a televised statement Tuesday, Nov. 26, 2024, in Jerusalem, Israel. Even as Israeli, U.S, Lebanese and international officials have expressed growing optimism over a ceasefire, Israel has continued its campaign in Lebanon, which it says aims to cripple Hezbollah’s military capabilities. An Israeli strike on Tuesday leveled a residential building in the central Beirut district of Basta — the second time in recent days warplanes have hit the crowded area near the city’s downtown. At least seven people were killed and 37 wounded, according to Lebanon's Health Ministry. Strikes on Beirut's southern suburbs killed at least one person and wounded 13, it said. Three people were killed in a separate strike in Beirut and three in a strike on a Palestinian refugee camp in southern Lebanon. Lebanese state media said another 10 people were killed in the eastern Baalbek province. Israel says it targets Hezbollah fighters and their infrastructure. Israel also struck a building in Beirut's bustling commercial district of Hamra for the first time, hitting a site that is around 400 meters (yards) from Lebanon’s Central Bank. There were no reports of casualties. The Israeli military said it struck targets in Beirut and other areas linked to Hezbollah's financial arm. The evacuation warnings covered many areas, including parts of Beirut that previously have not been targeted. The warnings, coupled with fear that Israel was ratcheting up attacks before a ceasefire, sent residents fleeing. Traffic was gridlocked, and some cars had mattresses tied to them. Dozens of people, some wearing their pajamas, gathered in a central square, huddling under blankets or standing around fires as Israeli drones buzzed loudly overhead. Hezbollah, meanwhile, kept up its rocket fire, triggering air raid sirens across northern Israel. Israeli military spokesman Avichay Adraee issued evacuation warnings for 20 buildings in Beirut's southern suburbs, where Hezbollah has a major presence, as well as a warning for the southern town of Naqoura where the U.N. peacekeeping mission, UNIFIL, is headquartered. UNIFIL spokesperson Andrea Tenenti told The Associated Press that peacekeepers will not evacuate. A police bomb squad officer inspects the site where a rocket fired from Lebanon landed in a backyard in Kiryat Shmona, northern Israel, Tuesday Nov. 26, 2024. The Israeli military also said its ground troops clashed with Hezbollah forces and destroyed rocket launchers in the Slouqi area on the eastern end of the Litani River, a few kilometers (miles) from the Israeli border. Under the ceasefire deal, Hezbollah would be required to move its forces north of the Litani, which in some places is about 30 kilometers (20 miles) north of the border. Hezbollah began firing into northern Israel, saying it was showing support for the Palestinians, a day after Hamas carried out its Oct. 7, 2023, attack on southern Israel, triggering the Gaza war. Israel returned fire on Hezbollah, and the two sides have been exchanging barrages ever since. Israel escalated its campaign of bombardment in mid-September and later sent troops into Lebanon, vowing to put an end to Hezbollah fire so tens of thousands of evacuated Israelis could return to their homes. More than 3,760 people have been killed by Israeli fire in Lebanon the past 13 months, many of them civilians, according to Lebanese health officials. The bombardment has driven 1.2 million people from their homes. Israel says it has killed more than 2,000 Hezbollah members. Hezbollah fire has forced some 50,000 Israelis to evacuate in the country’s north, and its rockets have reached as far south in Israel as Tel Aviv. At least 75 people have been killed, more than half of them civilians. More than 50 Israeli soldiers have died in the ground offensive in Lebanon. Chehayeb and Mroue reported from Beirut. Associated Press reporters Lujain Jo and Sally Abou AlJoud in Beirut contributed. Copyright 2024 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission. Stay up-to-date on the latest in local and national government and political topics with our newsletter.ESPN in major broadcasting change causing bitter blow to rivals NBC over College Football Playoff schedule
Bieber re-signs with GuardiansDocusign Announces Third Quarter Fiscal 2025 Financial ResultsWINNIPEG — Kyle Walters doesn’t believe losing a third consecutive Grey Cup means the Winnipeg Blue Bombers’ roster should be blown up. The CFL club’s general manager told reporters at his year-end availability Tuesday that reaching a fifth straight championship game by overcoming lots of injuries was a big accomplishment. Even before Winnipeg’s recent 41-24 Grey Cup loss to the Toronto Argonauts, Walters said he was looking forward to next season. “I was excited for next year based on what I’m looking at, compared to years past, where we’ve got more young guys that have contributed that are under contract,” he said. “We’ve got more young players in the building. So, the idea of, ‘This is the end of the road. The team is in a free-for-all downward,’ I don’t think is accurate. “We have a good group of guys and we were in a one-point (Grey Cup) game with 10 minutes left ... before things went downhill.” The Blue Bombers started the season 0-4, moved to 2-6 and finished 11-7 to claim the West Division title. Star receiver Dalton Schoen, veteran linebacker Adam Bighill and backup quarterback Chris Streveler all suffered season-ending injuries and are pending free agents. Negotiating with the team’s 27 unsigned players could be impacted by moves across the league among coaches, personnel staff and players such as quarterbacks, Walters said. The Bombers have given permission for offensive coordinator Buck Pierce to speak to the B.C. Lions and Edmonton Elks about those teams’ vacant head-coaching jobs, he said. Walters also revealed the Ottawa Redblacks were given the go-ahead to talk to Richie Hall about their defensive coordinator vacancy. Hall was a Winnipeg defensive assistant this season after Jordan Younger took over from him as defensive coordinator. Walters said the Bombers received permission to speak to Lions offensive coordinator Jordan Maksymic in case Pierce leaves. The Hamilton Tiger-Cats have already been given the OK to talk to Winnipeg assistant general managers Danny McManus and Ted Goveia about the Ticats’ GM opening. “You’re hesitant to have too much conversation with people who may not be in the organization next year, so it’s just been me and (head coach) Mike (O’Shea) in this moment huddled together and talking about next year,” Walters said. He said an NFL team had asked Tuesday morning to work out one Blue Bomber, but he didn’t reveal the player’s name in case he wasn’t aware of the request yet. The Blue Bombers won the Grey Cup in 2019 and ’21, but lost 28-24 to the Montreal Alouettes last year and 24-23 to Toronto in 2022. Winnipeg re-signed placekicker Sergio Castillo last week. Walters said he’d like to have deals done with three or four main players before the end of the year. The team has some up-and-coming young players inked for next year, and injuries gave others valuable experience on both sides of the ball, Walters said. Receivers such as rookie Ontaria Wilson (1,026 yards receiving in 18 games) and Keric Wheatfall (273 yards in seven games) are signed through next season. “The experience that they got was invaluable,” Walters said. Re-signing players who missed time because of injuries can get tricky. “Organizationally, can we approach (their agents) and say, ‘Well, your guy was hurt, he should come back for less money?’” Walters said. “Generally, they don’t view it like that. They view that they’ll be back 100 per cent.” One question mark is the backup to starting quarterback Zach Collaros, who suffered a deep cut to the index finger of his throwing hand late in the third quarter of the Grey Cup. Collaros got five stitches and numbing agent applied to his finger. He returned with a bandage on it, but admitted he had a hard time gripping the ball. “We’ll have to find out who our offensive coordinator is first,” Walters said when asked who might be Collaros’s backup. Terry Wilson, who briefly replaced Collaros in the Grey Cup, and Jake Dolegala are signed for next year. This report by The Canadian Press was first published Nov. 26, 2024. Judy Owen, The Canadian Press
Evaluating strategic options for iopofosine I 131 a late-stage clinical program with compelling Phase 2 data and a substantial market opportunity Focusing on advancing radiotherapeutic assets including alpha- and Auger-emitting radioconjugates into Phase 1 solid tumor studies FLORHAM PARK, N.J., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announces a strategic update on its clinical development programs for its proprietary phospholipid ether drug conjugate platform that delivers a broad array of therapeutic modalities to target cancers. Due to recent communications with the U.S. Food and Drug Administration (FDA, or the Agency) regarding a confirmatory study to support accelerated approval and the regulatory submission for iopofosine I 131, the Company has decided to pursue strategic options for the further development and commercialization of this product candidate. The CLOVER-WaM study was conducted in accordance with earlier FDA communications from an end of Phase 2 meeting and from a meeting in early 2024, during which the Company was informed that positive results for major response rate (MRR) as the primary endpoint could be acceptable to support accelerated approval of iopofosine I 131 as a treatment for Waldenstrom’s macroglobulinemia (WM). Based upon a recent Type-C meeting with the FDA, the Company now believes that a submission seeking accelerated approval would need to be based on the MRR data from CLOVER-WaM and enrollment in a randomized, controlled confirmatory study that is designed to generate data on progression-free survival (PFS). “While iopofosine I 131’s positive WM data along with the high unmet medical need for these patients support further investment, we have determined that such a program may best be brought to market by a larger organization with greater resources. Importantly, partnering or divesting this program supports our commitment to providing this potentially life-saving drug to the patients who need it as quickly as possible,” stated James Caruso, president and CEO of Cellectar. “We believe iopofosine I 131 represents a compelling opportunity as it has shown strong efficacy and good tolerability based on our clinical studies. Moreover, the commercial work we conducted demonstrates iopofosine I 131’s substantial market opportunity based upon the product profile, which includes off-the-shelf global distribution, orphan pricing and existing unmet medical need.” Cellectar remains confident in the potential of its phospholipid ether drug conjugate platform and the targeted radiotherapies in its development pipeline. Iopofosine I 131’s clinical success validates the platform’s ability to target cancers and Cellectar will leverage its experience to focus on the development of its earlier clinical programs. Specifically, Cellectar will focus on those assets it believes have the highest therapeutic potential and opportunity for value creation. As highlighted by recent acquisitions and collaborations within the radiopharmaceutical sector, precision isotopes like alpha- and Auger-emitters have emerged as the leading therapeutics of interest. Consequently, the Company will now focus its resources on targeting solid tumors by advancing CLR 121225, its actinium-225 based program, and CLR 121125, its iodine-125 Auger-emitting program into the clinic. Cellectar expects to file Investigational New Drug applications in the first half of 2025 for both CLR-121225 and CLR-121125, which will allow the initiation of Phase 1 clinical studies in solid tumor cancers. Both programs have demonstrated robust in vivo activity, tolerability, excellent targeting and uptake in preclinical solid tumor models. The Company believes this approach will provide an expedited timeframe to achieve safety and proof-of-concept data in patients. The Company’s strategic reprioritization will impact all departments and result in an immediate reduction in headcount of approximately 60%, which should be complete by the end of the fourth quarter 2024. The Company anticipates that the implementation of the restructuring will extend its cash runway into the third quarter of 2025. “We are being methodical in our efforts to reorganize the company with the goal of conserving cash while maintaining the flexibility to execute immediate priorities and build for long-term growth and value creation. This reorganization is difficult but necessary for the future growth potential of Cellectar,” said Mr. Caruso. “I want to extend my deepest gratitude to our departing employees for their significant contributions to our work and their dedication to making a difference in the lives of patients.” About Cellectar Biosciences, Inc. Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer, independently and through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug ConjugateTM (PDC) delivery platform to develop the next-generation of cancer cell-targeting treatments, delivering improved efficacy and better safety as a result of fewer off-target effects. The company’s product pipeline includes lead asset, iopofosine I 131, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), CLR 121225, an actinium-225 based program being targeted to several solid tumors with significant unmet need, such as pancreatic cancer, CLR 121125, an iodine-125 Auger-emitting program targeted in other solid tumors, such as triple negative breast, lung and colorectal, proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets. In addition, iopofosine I 131 is under evaluation in Phase 2b studies for relapsed or refractory multiple myeloma (MM) and central nervous system (CNS) lymphoma, alongside the CLOVER-2 Phase 1b study, targeting pediatric patients with high-grade gliomas, for which Cellectar is eligible to receive a Pediatric Review Voucher from the FDA upon approval. The FDA has also granted iopofosine I 131 Orphan Drug and Fast Track Designations for various cancer indications. New data from the CLOVER-WaM Phase 2 clinical trial were recently presented in an oral presentation at the 66th American Society of Hematology Annual Meeting and Exposition (ASH 2024). For more information, please visit www.cellectar.com or join the conversation by liking and following us on the company’s social media channels: Twitter, LinkedIn, and Facebook. Forward-Looking Statement Disclaimer This news release contains forward-looking statements. You can identify these statements by our use of words such as "may," "expect," "believe," "anticipate," "intend," "could," "estimate," "continue," "plans," or their negatives or cognates. These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to raise additional capital, uncertainties related to the disruptions at our sole source supplier of iopofosine, the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, patient enrollment and the completion of clinical studies, the FDA review process and other government regulation, our ability to obtain regulatory exclusivities, the availability of priority review vouchers, our ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement. A complete description of risks and uncertainties related to our business is contained in our periodic reports filed with the Securities and Exchange Commission including our Form 10-K/A for the year ended December 31, 2023, and our Form 10-Q for the quarter ended September 30, 2024. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update any such forward-looking statements. Contacts MEDIA: Christy Maginn Bliss Bio Health 703-297-7194 cmaginn@blissbiohealth.com INVESTORS: Anne Marie Fields Precision AQ 212-362-1200 annemarie.fields@precisionaq.comDexter: Original Sin will take audiences back in time to find out how the man became the monster — er, the monster-slayer — in the Showtime thriller. The prequel series, which premieres on Paramount+ with Showtime on Friday, December 13, takes place 15 years before we first met Dexter (then played by Michael C. Hall , who still narrates the new series) in the original Dexter . Taking over the title role in this iteration is Patrick Gibson , who has the character’s steely-eyed stares and smug sauntering style down to a science. With new characters being introduced in some familiar settings, the new series will bring some new details about Dexter’s past to light, but it will also inevitably retread some familiar territory from the first show, which had ample flashbacks. Here’s what to remember about Dexter ‘s past before Dexter: Original Sin . Dexter didn’t find out until he was a fully grown serial murderer that he had a big brother who was also running around slaughtering people. The Ice Truck Killer who stalked Dexter was actually Brian Moser, his slightly older brother who was not adopted (or even mentioned) by Harry. Dexter only found out about Brian because the Ice Truck Killer left clues that were tailored to catch his attention — reminding him of scenes from his past as part of the Morgan family. Laura Moser was the single mother to Brian and Dexter and worked as a confidential informant for Harry and the Miami-Metro Police Department against the Colombian cartel. She was brutally dismembered right in front of Brian and Dexter, who were left wading in her blood inside a shipping container. Harry adopted Dexter as his own upon finding him in the container, but Brian was sent into the foster system. In flashbacks in Dexter , it became clear that he was not a normal teenager with typical feelings or tendencies. In fact, he had an innate bloodlust that his father recognized and tried to quell with hunting trips, to the exclusion of his daughter Debra. Harry wanted to protect Dexter from himself — particularly his self-destructive impulses. 'Dexter: Original Sin' Clip Reveals Dex's First Day on the Job Though Harry tried to find other ways for Dexter to quench his thirst for blood, so to speak, he soon gave in and encouraged him to kill someone when he discovered Nurse Mary was poisoning Harry and other patients in the hospital after his heart attack. Once Dexter began to kill, Harry worked hard to create a framework for his adoptive son to work within that, if he followed it to the letter, would keep his morality and freedom intact. The rules included being certain that the mark was worthy of being murdered and leaving no trace of evidence behind. Even after Harry’s death, Dexter worked to strictly adhere to this code in every kill. Randy Tepper/Showtime Dexter repeatedly revealed that he felt empty on the inside, and it was Harry who taught him to feign normal human feelings and social interactions around others — even if it meant faking a smile in his own family photos. Little by little throughout Dexter , we learn that Harry Morgan had several affairs while married to Doris, including with Laura Morgan and another confidential informant. Though Harry is definitely the most common star of Dexter’s flashback memories, his adoptive mother Doris is also a fixture of his past. She died when Deb was 16 and didn’t know about Dexter’s violent tendencies, even if she didn’t totally understand him at times. Dexter: Original Sin , Series Premiere, Streaming, Friday, December 13, Paramount+ with Showtime, Sunday, December 15, 10/9c, Paramount+ with Showtime More Headlines: 8 Things to Remember About Dexter’s Childhood Before ‘Original Sin’ Ryan Seacrest Reveals Dating Status to Shocked ‘Wheel of Fortune’ Contestants Your Chance to Win ‘Blue Bloods’ Collector’s Issue Signed by Bridget Moynahan Holly Robinson Peete Makes ‘Home Alone’ Confession in ‘LEGO Masters Holiday Bricktacular’ Sneak Peek (VIDEO) ‘Jeopardy!’ Boss Announces Solution to Big Tournament of Champions Problem
- Previous: disney magic oceanview room
- Next: flik flak magical ocean
